About
Our Story
Our People
Careers
Science
Our Science
Pipeline
Izokibep
Lonigutamab
SLRN-517
Publications
Community
Patients
Partnerships
Investors
For Investors
Press Releases
Events
News Center
News Center
Media Kit
Contact
News Center
All
Company News
Press Releases
Events
Publications & Presentations
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
Press Release
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
Read more
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
Press Release
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
Read more
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
Press Release
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
Read more
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
Press Release
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
Read more
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
Press Release
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
Read more
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Read more
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Press Release
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Read more
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
Press Release
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
Read more
ACELYRIN, INC. Reports First Quarter 2023 Financial Results And Recent Highlights
Press Release
ACELYRIN, INC. Reports First Quarter 2023 Financial Results And Recent Highlights
Read more
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Press Release
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read more
ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering
Press Release
ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering
Read more
ACELYRIN, INC. Announces Launch of IPO Roadshow
Press Release
ACELYRIN, INC. Announces Launch of IPO Roadshow
Read more
ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy
Press Release
ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy
Read more
Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors
Press Release
Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors
Read more
ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa
Read more
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
Press Release
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
Read more
Load More